Risk factors for steroid-refractory in immune checkpoint inhibitor-induced colitis: a retrospective cohort study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) represent an effective treatment for various malignant tumors. However, the utilization of ICIs is frequently accompanied by immune-related adverse events (irAEs), among which immune checkpoint inhibitor (ICI)-induced colitis is a notable complication. Current clinical guidelines recommend corticosteroids as the first-line therapy for ICI-induced colitis. Nevertheless, subset of patients fails to respond adequately to corticosteroid therapy, resulting in steroid refractoriness. At present, studies investigating the risk factors for steroid-refractory remain limited.

Patients and methods

A retrospective analysis was conducted on patients diagnosed with ICI-induced colitis after malignant tumor treatment with ICIs. Data collected

SUBMITTER: Meng K 

PROVIDER: S-EPMC12537882 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature